LAVAL, QC and CAMBRIDGE, England, July 17, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, ...
LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseases Advancement of clinical trial application (CTA) ...
When it comes to enabling secure AI usage for SMBs, Liminal fills a major need for MSPs that are looking to stay relevant in the AI conversation, an MSP executive tells CRN. Secure AI platform Liminal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results